ワークショップ9 EGFR遺伝子変異陽性肺癌に対する治療戦略

[WS9-6] Osimertinib±platinum-pemetrexed in EGFRm advanced NSCLC：FLAURA2 post-progression outcomes

^○Satoshi Oizumi¹, Natalia Valdiviezo², Isamu Okamoto³, Brett G. M. Hughes⁴, Samreen Ahmed⁵, Lin Wu⁶, Jie Hu⁷, Renzo Alvarez⁸, Ki Hyeong Lee⁹, Xuan Dung Pham¹⁰, Rohan Bhise¹¹, Myung-Ju Ahn¹², Glaucio Bertollo¹³, Yuichi Tambo¹⁴, Rubi Li¹⁵, Alexander Todd¹⁶, Dakshayini Kulkarni¹⁶, Neha P. Amin¹⁷, David Planchard¹⁸, Pasi A. Jänne¹⁹, Kunihiko Kobayashi²⁰ (1.Hokkaido Cancer Center, Sapporo, Japan, 2.Instituto Nacional de Enfermedades Neoplasicas, Surquillo, Peru, 3.Kyushu University, Fukuoka, Japan, 4.The Prince Charles Hospital, and University of Queensland, Brisbane, Australia, 5.University Hospitals of Leicester NHS Trust, Leicester, UK, 6.Hunan Province Tumor Hospital, Changsha, China, 7.Zhongshan Hospital Affiliated to Fudan University, Shanghai, China, 8.Centro Medico Monte Carmelo, Calle Francisco, Arequipa, Peru, 9.Chungbuk National University Hospital, Cheongju, Republic of Korea, 10.HCMC Oncology Hospital, Binh Thanh District, Ho Chi Minh City, Vietnam, 11.J N Medical College and KLES Dr. Prabhakar Kore Hospital and MRC, Nehru Nagar, Belagavi, India, 12.Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, 13.AFECC/Hospital Santa Rita, Vitória, Brazil, 14.Kanazawa University Hospital, Kanazawa, Japan, 15.St. Luke's Medical Center, Quezon City, Philippines, 16.AstraZeneca, Cambridge, UK, 17.AstraZeneca, Gaithersburg, MD, USA, 18.Université Paris-Saclay, Paris, France, 19.Dana-Farber Cancer Institute, Boston, MA, USA, 20.Saitama Medical University, Saitama, Japan)